



**CENTURY**  
THERAPEUTICS

# CORPORATE OVERVIEW

---

November 2021

# FORWARD-LOOKING STATEMENTS

---

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect the our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our reliance on the maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at [www.sec.gov](http://www.sec.gov). You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in the our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.



# CENTURY THERAPEUTICS - EMERGING LEADER IN iPSC CELL THERAPIES

**COMPREHENSIVE  
iPSC CELL PLATFORM**  
FOR IMMUNE  
EFFECTOR CELLS

**PRODUCT CANDIDATE ENGINE**  
WITH PIPELINE IN SOLID AND  
HEMATOLOGIC MALIGNANCIES

**LEAD PROGRAM**  
ON TRACK TO FILE IND  
MID 2022

**EXPERTISE**  
GENETIC & PROTEIN ENGINEERING,  
PROCESS DEVELOPMENT, AND  
IMMUNO-ONCOLOGY


**STATE-OF-THE ART GMP  
MANUFACTURING FACILITY EXPECTED  
TO BE OPERATIONAL 1Q 2022**

**HEADQUARTERED IN  
PHILADELPHIA**  
WITH CENTERS OF EXCELLENCE  
IN SEATTLE AND ONTARIO

**\$400.3M**  
IN CASH, CASH EQUIVALENTS  
AND MARKETABLE  
SECURITIES AS OF 9/30/2021

**~150**  
EMPLOYEES INCLUDING  
EXPERIENCED LEADERS  
AND ENTREPRENEURS

# WE ARE BUILDING A NEXT GENERATION CELL THERAPY PLATFORM



## NEXT GENERATION ALLOGENEIC iPSC-BASED PLATFORM

Hypoimmunogenic products generated with Allo-Evasion™ technology

### ALLO-EVASION™ PRODUCES HYPOIMMUNOGENIC CELLS

- To potentially prevent graft rejection by patient

### FIT-FOR-PURPOSE PRODUCTS WITH MULTIPLE GENE EDITS

- Cutting edge CRISPR gene editing

### MULTISPECIFIC TUMOR TARGETING

- CAR engineering with VHH technology

### CAR-iNK AND CAR-iT CELL PLATFORMS

- Access to both cell platforms provides optionality

# PROVEN LEADERSHIP TEAM

---



Osvaldo (Lalo) Flores, CEO



Hy Levitsky, President R&D



Adrienne Farid, COO



Greg Russotti, CTO



Luis Borges, CSO



Michael Diem, CBO

# FOUNDATIONAL INVESTMENTS IN iPSC KNOW-HOW AND MANUFACTURING

Significant acceleration of platform and product development

## iPSC License and collaboration agreement established in 2018

- Access to clinical grade iPSC lines
- Exclusive IP and know-how to generate immune effector cells using feeder-free methods (NK, T, Mac, DC)
- Dedicated FCDI GMP manufacturing capacity for Century's product candidates
- Leveraging two decades of research & investment at University of Wisconsin and FCDI



## In-House Manufacturing accelerates learnings and enables faster product iteration


- Century facility expected to be operational by early 2022
  - 53,000 ft<sup>2</sup> facility
  - Designed to produce multiple immune cell types
- Two sites provides optionality and maximizes flexibility





# iPSC TECHNOLOGY CAN OVERCOME LIMITATIONS OF DONOR DERIVED PLATFORMS

## Allogeneic, donor-derived




**Multiple donors**

**Fewer doses  
per batch**

- Complex manufacturing, heterogeneous product, limited scale
- Limited genetic engineering options

## Allogeneic, iPSC-derived



**Single Donor**

**Greater doses  
per batch**

- Efficient manufacturing, homogeneous product, greater scale
- Likely unlimited genetic engineering options

# CENTURY'S CRISPR-MEDIATED iPSC GENE EDITING

Highly uniform product candidates derived from fully characterized single-cell clones

## Proprietary CRISPR-MAD7 mediated homology directed repair (HDR)

- MAD7 licensed from Inscripta. Methodology developed at Century
- HDR technology enables precise gene KOs and transgene KIs
- CRISPR protein and guide RNAs delivered using RNP (non-viral)


## Fully characterized, homogeneous drug products

- Sequential gene editing steps allow:
  - Introduction of multiple gene modifications
  - Elimination of clones with chromosomal alterations and structural variants (i.e. translocations, inversions)

## Master cell banks (MCBs) generated from single-cell clones

- MCBs fully characterized and de-risked genetically
  - Whole genome sequencing
  - Copy number variation (CNV) analysis
  - Transgene copy number by ddPCR

## iPSC Precision Engineering




## CRISPR-mediated HDR (MAD7)



# OVERCOMING ALLOREACTIVITY CHALLENGES

## Current limitations




### Graft versus Host Disease (GvHD)

- Donor T cells damage patient's tissues

### Host versus graft Rejection

- Patient immune system eliminates allogeneic cells

## Century's solution




### Prevention of Graft versus Host Disease

- GvHD is circumvented with Trusted TCR

### Prevention of Allo-Rejection


- Allo-rejection is circumvented with Allo-evasion™ gene edits

# ALLO-EVASION™ 1.0 DESIGNED TO OVERCOME 3 MAJOR PATHWAYS OF HOST VS GRAFT REJECTION




- 1 Deletion of  $\beta$ 2M, a protein required to express HLA-I on the cell surface prevents recognition by CD8 T cells
- 2 Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells
- 3 Knock-in of HLA-E prevents killing by NK cells

# ILLUSTRATIVE POTENTIAL OF ALLO-EVASION™ ON CELLULAR PHARMACOKINETICS AND REPEAT DOSING



# CNTY-101: CAR-iNK CANDIDATE IN R/R B-CELL LYMPHOMA



## CNTY-101 may change the lymphoma treatment paradigm

- Has potential to use with milder lymphodepletion regimens
- Potential to re-dose to enhance efficacy
- Designed as an off-the-shelf cell therapy


## IND filing on track for mid-2022

- P1 in RR NHL set to initiate 2H22
- Generates POC for CAR iNK platform and allo-evasion technology





# iNK CELL PLATFORM IS OUR MOST ADVANCED PLATFORM

CNTY-101, our first product candidate is a CAR-iNK cell engineered with multiple features



# CENTURY iT CELL PLATFORM: TrueT CELLS WITH TRUSTED TCRs

Currently Exploring Two Major T Cell Subsets To Develop Century's iT Cell Platform




Unique features of Century's iT cell platform:

- Retention of a functional TCR intended to improve iT cell differentiation and functionality
- Use of Trusted  $\alpha\beta$  and  $\gamma\delta$  which are not expected to mediate GVHD


# CAR-iT CELL PLATFORM: $\gamma\delta$ CAR-IT CELLS

$\gamma\delta$  iT cells is one of the T cell platform options we are exploring to generate TrueT cells


## Differentiation of $\gamma\delta$ CAR-iT cells from T-iPSC



## TrueT Cells






## True CAR-iT cells kill lymphoma cells similarly to peripheral blood CAR-T cells



# iPSC-DERIVED $\gamma\delta$ iT CELLS MEDIALTE SERIAL KILLING AGAINST LYMPHOMA CELLS


$\gamma\delta$  CAR-iT and PBMC CAR-T cells have similar serial killing activity over 10 rounds of tumor cell killing





# OUR iT CELL PLATFORM IS CLOSE BEHIND AND MAKING DEMONSTRABLE PROGRESS

Developing  $\alpha\beta$  and  $\gamma\delta$  iT platforms with Trusted TCRs that are not expected to cause GvHD



# PIPELINE

Product candidate pipeline across cell platforms and targets in solid and hematologic cancers

Product	iPSC Platform	Targets	Indications	Ownership	Expected IND Submission	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
CNTY-101	iNK	CD19	Lymphoma	 CENTURY THERAPEUTICS	Mid 2022					
CNTY-103	iNK	CD133 + EGFR	Glioblastoma	 CENTURY THERAPEUTICS	1H 2023					
CNTY-102	iT or iNK	CD19 + CD79b	Lymphoma	 CENTURY THERAPEUTICS	2H 2023					
CNTY-104	iT or iNK	Multi-specific	Acute Myeloid Leukemia	 CENTURY THERAPEUTICS	1H 2024					



Solid Tumors





Hematologic Tumors

# CATALYSTS

---

Event	Estimated Timing
Close IPO with gross proceeds of \$243M	2Q21 ✓
Solicit Pre-IND written feedback for CNTY-101	3Q21 ✓
CNTY-101 entered IND enabling studies and manufacturing	4Q21 ✓
<b>cGMP manufacturing facility in Branchburg NJ expected to be operational</b>	<b>1Q22</b>
<b>In vivo POC for CNTY-103</b>	<b>1H22</b>
<b>CNTY-101 IND filing</b>	<b>Mid-2022</b>
<b>Initiate CNTY-101 P1 study R/R NHL</b>	<b>2H22</b>
<b>Preliminary safety from CNTY-101 P1</b>	<b>1H23</b>

# CENTURY'S NEXT GENERATION iPSC TECHNOLOGY PLATFORM





The background is a deep blue field filled with a complex network of thin, branching, light blue lines that resemble a microscopic view of tissue or a neural network. In the center, there is a prominent, dense cluster of cells. This cluster has a rough, irregular surface with many small, rounded protrusions. A smaller, more spherical cell is positioned to the left of the main cluster, appearing to be in contact with it. The overall image has a scientific, high-tech feel.

# THANK YOU

---